MedTrace Logo

Evaluation of XYA02 in Patients With Advanced Solid Tumors

NCT07670312 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2026-07-13

No results posted yet for this study

Summary

This study will evaluate the safety, tolerability, and efficacy of XYA02 in participants with advanced solid tumors.

Conditions

Interventions

BIOLOGICAL

XYA02

IV infusion

Sponsors & Collaborators

  • Novotech (Australia) Pty Limited

    collaborator INDUSTRY

  • XYone Therapeutics, Inc

    lead INDUSTRY

Principal Investigators

  • Patrick A Zweidler-McKay, MD/PhD · XYone Therapeutics, Inc

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-15
Primary Completion
2029-07-15
Completion
2030-07-15

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07670312 on ClinicalTrials.gov